Pfizer Consumer Healthcare

Vanwall Road, Maidenhead, Berks, SL6 4UB
Telephone: +44(0)1628 692 002
Fax: +44(0)1628 414 728
Medical Information Direct Line: 0845 111 0151
Medical Information e-mail: carelineuk@pfizer.com
Customer Care direct line: 0845 111 0151
Medical Information Fax: +44(0)1628 414 728

Summary of Product Characteristics last updated on the eMC: 06/05/2010
SPC Anadin Original

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/05/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   27-Apr-2010
Legal Category:   P, GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change in Marketing Authorisation Holder name and address.
Updated on 21/01/2008 and displayed until 06/05/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.9 - Overdose
  • Change to section 6. 4 - Special Precautions for Storage
Date of revision of text on the SPC:   01/2008
Legal Category:   GSL/P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

To update sections 2; 4.2; 4.4; 4.9 and 6.4 of the SPC to bring in line with other Wyeth Products containing the same active ingredients.
Updated on 06/12/2007 and displayed until 21/01/2008
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
Date of revision of text on the SPC:   11/2007
Legal Category:   GSL/P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 
 
Increase in shelf life from 24 months to 36 months
Updated on 24/07/2006 and displayed until 06/12/2007
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   07/2006
Legal Category:   GSL/P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 
 
Section 4.9 overdose amended to reflect new amendments about symptoms and management of overdose for all active ingredients (Aspirin and Caffeine)
Updated on 29/09/2005 and displayed until 24/07/2006
Reasons for adding or updating:
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 28/09/2005 and displayed until 29/09/2005
Reasons for adding or updating:
  • Change to section 6. 4 - Special Precautions for Storage
  • Pending awaiting re-submission
Updated on 26/08/2005 and displayed until 28/09/2005
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6.1 - List of Excipients
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 (date of (partial) revision of the text
  • Pending awaiting re-submission
Updated on 07/01/2005 and displayed until 26/08/2005
Reasons for adding or updating:
  • Change to section 1 - trade name
Updated on 17/12/2004 and displayed until 07/01/2005
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
  • Pending awaiting re-submission

Active Ingredients/Generics

 
   caffeine
   acetylsalicylic acid